期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

我院2004年7月～2007年6月抗肿瘤药利用分析 被引量：2

Analysis of the Use of Anticancer Drugs in Our Hospital from July 2004 to June 2007
原文传递
导出
摘要 目的:评价我院抗肿瘤药的应用现状及趋势。方法:对我院2004年7月～2007年6月抗肿瘤药的销售金额、用药频度等进行统计、分析。结果:抗肿瘤药销售金额2004～2007年呈逐年上升趋势;抗肿瘤辅助药应用比例较大;一些新型抗肿瘤植物药、抗代谢药等逐渐应用于临床。结论:我院抗肿瘤药品种基本固定,抗肿瘤植物药、单克隆抗体药和基因工程药物将成为日后治疗肿瘤的主要药物。 OBJECTIVE： To evaluate the status quo and trend of the use of anticancer drugs in our hospital. METHODS： The anticancer drugs used in our hospital from July 2004 to June 2007 were analyzed in respect to the consumption sum and DDDs etc. RESULTS： The consumption sum of anticancer drugs increased year by year, with anticancer assistant drugs showing high proportion, and some new anticancer drugs derived from natural plants and antimetabolites have been increas- ingly used in the clinic. CONCLUSION ： The variety of the anticancer drugs in our hospital is stable, and the anticancer drugs derived from natural plants, the monoclonal antibody medicine and the genetically engineered drug are expected to become the predominant therapy for cancer treatment.
作者 曾春生
机构地区 江西赣州市肿瘤医院
出处 《中国药房》 CAS CSCD 北大核心 2008年第32期2494-2496,共3页 China Pharmacy
关键词 抗肿瘤药 用药分析 销售金额 用药频度 Anticancer drugs Analysis of drug use Consumption sum DDDs
分类号 R969.1 [医药卫生—药理学]
  • 相关文献

参考文献6

二级参考文献58

  • 1储大同.生物和基因治疗[A].孙燕周际昌主编.临床肿瘤内科治疗手册:第4版[C].北京:人民卫生出版社,2003.74-89.
  • 2[1]Seidman AD,Tiersten A,Hudis C,et al. Phase Ⅱtrial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J].J Clin Oncol, 1995,13(10):2 575.
  • 3[5]Robert N,Leyland-Jones B, Asmar L,et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer[J].Breast Cancer Res Treat, 2002,76(supple): 37.
  • 4[6]Seidman AD, Fornier MN, Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification[J].J Clin Oncol,2001,19(10):2 587.
  • 5[7]Henderson C,Berry DA,Demetri GD,et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol,2003,21 (6): 976.
  • 6[8]Nabholtz JM,Pienkowski T,Mackey J,et al. Phase Ⅲ trial comparing TAC (docetaxel, doxorubicin,cyclophosphamide) with FAC (5-fluorouracil,doxorubicin,cyclophospha-mide) in the adjuvant treatment of node positive breast cancer(BC)patients: interim analysis of the BCIRG 001 study[A].ASCO, 2002,21:141 abstr.
  • 7[9]Pirker R, Krajnik G, Zochbauer S, et al. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC) [J].Ann Oncol, 1995,6(8):833.
  • 8[12]van Oosterom AT.Docetaxel(taxotere) and gemcitabine phase Ⅰ and early phase Ⅱ studies: results to date and an overview of ongoing studies[J].Semin Oncol, 1999,26(3 suppl 11): 8.
  • 9[15]Fossella FV,Belani CP.Phase Ⅲ study(TAX 326)of docetaxel-cisplatin and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin(VC) for the firstline treatment of advanced/metastatic non-smallcell lung cancer(NSCLC):analyses in elderly patients[A].ASCO,2003, 22:2 528 abstr.
  • 10[16]Ishikawa H,Nakanishi TT,Nawa A,et al.3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer[J].Int J Clin Oncol,2001,6(3): 128.

共引文献71

同被引文献14

引证文献2

二级引证文献17

中国药房
2008年 第32期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部